Laboratorios Richmond S.A.C.I.F. (BCBA:RICH)

Market Cap	134.05B +4.4%
Revenue (ttm)	126.73B +4.9%
Net Income	3.09B -90.2%
EPS	38.24 -90.2%
Shares Out	80.75M
PE Ratio	55.76
Forward PE	n/a
Dividend	26.89 (1.62%)
Ex-Dividend Date	n/a

Volume	500
Average Volume	15,281
Open	1,705.00
Previous Close	1,660.00
Day's Range	1,695.00 - 1,705.00
52-Week Range	945.00 - 2,300.00
Beta	-0.70
RSI	41.44
Earnings Date	Mar 26, 2026

About BCBA:RICH

Laboratorios Richmond S.A.C.I.F., a pharmaceutical company, develops and manufactures pharmaceutical products. It provides antiretroviral products for the treatment of human immunodeficiency virus (HIV); oncology and oncohematology drugs; cardiometabolic drugs, including antihypertensive, hypocholesterolemic, platelet antiaggregants, and hypoglycemic drugs; and neurological and psychiatric drugs comprising analgesic, antipsychotic, antidepressants, anti-dementia, antiepileptics, and hypnotic drugs, as well as drugs for the treatment of multiple...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1935
• Employees: 620
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: RICH

Financial Performance

In 2025, BCBA:RICH's revenue was 126.73 billion, an increase of 4.95% compared to the previous year's 120.75 billion. Earnings were 3.09 billion, a decrease of -90.16%.